Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

BI and Inventiva collaborate to treat IPF

Executive Summary

Boehringer Ingelheim GMBH and Inventiva Pharma will collaborate to develop treatments for idiopathic pulmonary fibrosis (IPF) and other pulmonary diseases. The multi-year deal is valued at up to €170mm including an undisclosed up-front payment along with research funding, research, development, regulatory and commercial milestone payments, and tiered royalties on sales.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • OTC, Consumer
  • Biotechnology
    • Drug Discovery Tools
    • Pharmacogenetics-Pharmacogenomics
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies